Literature DB >> 20437148

In vivo studies with a Candida tropicalis isolate exhibiting paradoxical growth in vitro in the presence of high concentration of caspofungin.

Sedigh Bayegan1, Laszlo Majoros, Gabor Kardos, Adam Kemény-Beke, Cecilia Miszti, Renato Kovacs, Rudolf Gesztelyi.   

Abstract

We investigated the activity of caspofungin against a Candida tropicalis clinical isolate showing paradoxical growth in vitro. BALB/c mice immunosuppressed by cyclophosphamide were infected intraperitoneally using 10(7) CFU/mouse. Caspofungin was administered intraperitoneally once daily for 5 days or as a single dose using the following doses: 0.12, 0.25, 1, 2, 3, 5, and 15 mg/kg. The single dose of caspofungin was effective only at 5 and 15 mg/kg concentrations (100% survival). Five-day caspofungin treatment led to 100% survival at doses of 1 mg/kg or higher. Caspofungin treatment significantly decreased the number of viable yeasts in the peritoneal lavage samples as well as in the infected abscesses at doses 1, 3, 5, and 15 mg/kg caspofungin as compared to the untreated control (P<0.001 in all cases), and even to the group treated with 0.12 mg/kg caspofungin (P<0.05 in all cases). At 2 mg/kg caspofungin dose, sterilization of the internal organs was reproducibly incomplete, suggesting that the role of paradoxical growth in the late clinical failure cannot be excluded.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20437148     DOI: 10.1007/s12275-010-9221-y

Source DB:  PubMed          Journal:  J Microbiol        ISSN: 1225-8873            Impact factor:   3.422


  13 in total

1.  Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin.

Authors:  David A Stevens; Masayuki Ichinomiya; Yukako Koshi; Hiroyuki Horiuchi
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

2.  Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia.

Authors:  Ruta Petraitiene; Vidmantas Petraitis; Andreas H Groll; Tin Sein; Robert L Schaufele; Andrea Francesconi; John Bacher; Nilo A Avila; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

3.  In vitro study of Candida tropicalis isolates exhibiting paradoxical growth in the presence of high concentrations of caspofungin.

Authors:  G Sóczó; G Kardos; I Varga; B Kelentey; R Gesztelyi; L Majoros
Journal:  Antimicrob Agents Chemother       Date:  2007-10-08       Impact factor: 5.191

4.  Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity.

Authors:  Arnold Louie; Mark Deziel; Weiguo Liu; Michael F Drusano; Tawanda Gumbo; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

5.  Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872).

Authors:  R Hajdu; R Thompson; J G Sundelof; B A Pelak; F A Bouffard; J F Dropinski; H Kropp
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

6.  Assessment of the paradoxical effect of caspofungin in therapy of candidiasis.

Authors:  Karl V Clemons; Marife Espiritu; Rachana Parmar; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

7.  Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations.

Authors:  David A Stevens; Marife Espiritu; Rachana Parmar
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

8.  Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity.

Authors:  Nathan P Wiederhold; Dimitrios P Kontoyiannis; Jingduan Chi; Randall A Prince; Vincent H Tam; Russell E Lewis
Journal:  J Infect Dis       Date:  2004-09-10       Impact factor: 5.226

9.  Caspofungin.

Authors:  Stanley C Deresinski; David A Stevens
Journal:  Clin Infect Dis       Date:  2003-05-19       Impact factor: 9.079

10.  Caspofungin for the treatment of less common forms of invasive candidiasis.

Authors:  Oliver A Cornely; Martin Lasso; Robert Betts; Nickolay Klimko; Jose Vazquez; Geoff Dobb; Juan Velez; Angela Williams-Diaz; Joy Lipka; Arlene Taylor; Carole Sable; Nicholas Kartsonis
Journal:  J Antimicrob Chemother       Date:  2007-05-26       Impact factor: 5.790

View more
  10 in total

1.  Paradoxical effect of caspofungin against Candida bloodstream isolates is mediated by multiple pathways but eliminated in human serum.

Authors:  Ryan K Shields; M Hong Nguyen; Chen Du; Ellen Press; Shaoji Cheng; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2011-03-21       Impact factor: 5.191

2.  Paradoxical growth of Candida albicans in the presence of caspofungin is associated with multiple cell wall rearrangements and decreased virulence.

Authors:  Cristina Rueda; Manuel Cuenca-Estrella; Oscar Zaragoza
Journal:  Antimicrob Agents Chemother       Date:  2013-12-02       Impact factor: 5.191

Review 3.  The potential impact of antifungal drug resistance mechanisms on the host immune response to Candida.

Authors:  Russell E Lewis; Pierluigi Viale; Dimitrios P Kontoyiannis
Journal:  Virulence       Date:  2012-06-22       Impact factor: 5.882

Review 4.  An Update on Candida tropicalis Based on Basic and Clinical Approaches.

Authors:  Diana L Zuza-Alves; Walicyranison P Silva-Rocha; Guilherme M Chaves
Journal:  Front Microbiol       Date:  2017-10-13       Impact factor: 5.640

Review 5.  Treatment of Invasive Candidiasis: A Narrative Review.

Authors:  Ronen Ben-Ami
Journal:  J Fungi (Basel)       Date:  2018-08-16

6.  Minimal Inhibitory Concentration (MIC)-Phenomena in Candida albicans and Their Impact on the Diagnosis of Antifungal Resistance.

Authors:  Ulrike Binder; Maria Aigner; Brigitte Risslegger; Caroline Hörtnagl; Cornelia Lass-Flörl; Michaela Lackner
Journal:  J Fungi (Basel)       Date:  2019-09-04

7.  Efficacy of humanized single large doses of caspofungin on the lethality and fungal tissue burden in a deeply neutropenic murine model against Candida albicans and Candida dubliniensis.

Authors:  Eszter Prépost; Zoltán Tóth; David S Perlin; Rudolf Gesztelyi; Gábor Kardos; Renátó Kovács; Fruzsina Nagy; Lajos Forgács; László Majoros
Journal:  Infect Drug Resist       Date:  2019-07-01       Impact factor: 4.003

8.  Relative Frequency of Paradoxical Growth and Trailing Effect with Caspofungin, Micafungin, Anidulafungin, and the Novel Echinocandin Rezafungin against Candida Species.

Authors:  Zoltán Tóth; Lajos Forgács; Tamás Kardos; Renátó Kovács; Jeffrey B Locke; Gábor Kardos; Fruzsina Nagy; Andrew M Borman; Awid Adnan; László Majoros
Journal:  J Fungi (Basel)       Date:  2020-08-17

9.  Adaptation of the emerging pathogenic yeast Candida auris to high caspofungin concentrations correlates with cell wall changes.

Authors:  Violeta Lara-Aguilar; Cristina Rueda; Irene García-Barbazán; Sarai Varona; Sara Monzón; Pilar Jiménez; Isabel Cuesta; Ángel Zaballos; Óscar Zaragoza
Journal:  Virulence       Date:  2021-12       Impact factor: 5.882

Review 10.  Recent Insights into the Paradoxical Effect of Echinocandins.

Authors:  Johannes Wagener; Veronika Loiko
Journal:  J Fungi (Basel)       Date:  2017-12-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.